Panel Discussion
April 27, 2016 –
Expanding the definition of "value" beyond cost, Robert Dubois, MD, PhD, emphasized that clinical pathways need more dynamic quality metrics that provide more than just a snapshot of a patient's performance.
April 27, 2016 –
Panelists discussed whether there is any flexibility woven into the process of developing a clinical pathway, especially if a patient does not respond to a particular therapy or if a clinician wants to include a new therapy that may be better fit.
April 27, 2016 –
While providers would be relieved of their administrative burden, standardizing care pathways across health plans may not be an easy task, Blase Polite, MD, MPP, explains.
April 27, 2016 –
Have clinical pathways in oncology developed enough for providers and patients to use them as a shared decision-making tool? Panelists provide insight.
April 27, 2016 –
Experts discuss the need for guidelines and adequate rigor when developing a care pathway in oncology.
April 27, 2016 –
What do pathway developers consider as they formulate cancer clinical pathways? Panelists explain.
April 27, 2016 –
Panel members provide their own perspective on what clinical pathways encompass.
April 26, 2016 –
The American Journal of Managed Care convened an expert panel to discuss the development and utility of clinical pathways in oncology care.
February 12, 2015 –
Looking at the situation in hepatitis C and its potential impact on other conditions from a provider standpoint, Ed Cohen, PharmD, FAPhA, offers up many questions to which there may not be answers just yet.
February 12, 2015 –
The situation with hepatitis C drug costs is setting an interesting precedent for the rest of healthcare and one that needs to be watched closely, according to Keith Hoffman, PhD.
